Angered by the Supreme Court's decision to stop 157 clinical trials pharma companies are considering moving them out of India. It's believed that this uncertain scenario will in the long run harm India's image as a diverse location for clinical trials and also impact the availability of drugs in India. Dhananjay Bakhle Executive Vice-President (Medical Research) Novel Drug Discovery & Development Lupin Limited told The Indian Express 'The regulatory environment and volatility therein the uncertainty over the last two years was already discouraging and we started conducting clinical trials in other geographies such as Europe. If granted approvals are also